Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Better survival with hyperbaric oxygen therapy at 6 years

Elvira Manzano
30 Oct 2015

Hyperbaric oxygen therapy improves long-term survival in patients with chronic diabetic foot ulcers, according to 6-year follow-up data from the HODFU* study.

At 6 years, 63.2 percent of patients who received 37 of 40  hyperbaric oxygen treatments survived compared with 40.5 percent of those treated with placebo (p<0.05). [2015 European Association for the Study of Diabetes Annual Meeting, abstract 63]

“There was a statistically significant difference between patients treated with hyperbaric oxygen versus those treated with placebo,” said study author Dr. Magnus Löndahl from Lund University in Lund, Sweden. “In patients given hyperbaric oxygen, mortality was around 40 percent, and in those receiving placebo, mortality was around 60 percent.”

Chronic diabetic foot ulcer increases the risk for mortality, neuropathy and microvascular and macrovascular disease. A beneficial outcome of this study is that hyperbaric oxygen treatment appears to increase oxygen concentration in the tissue and hence, improves microvascular function.

To evaluate the long-term effects of hyperbaric oxygen therapy in chronic diabetic foot ulcer, patients were randomized to hyperbaric air or hyperbaric oxygen. Comorbidities were no different between groups at baseline as were prescriptions for diabetes and cardiovascular disease medications. Active treatment consisted of 40 sessions of 100 percent oxygen in hyperbaric chamber (90 minutes/day, 5 days/week for 8 weeks) or placebo carried out in air, both under 2.5 absolute atmospheres (ATA).

One-third of patients in both groups experienced sudden death, 20 percent died from infection, 20 percent from cancer, and 15 percent from acute myocardial infarction (MI).

Researchers said the findings need to be interpreted with caution, adding that more information are warranted before hyperbaric oxygen therapy can be offered in the clinic for patients with diabetic foot ulcer.

Dr. Giel Nijpels, session moderator from the Free University of Amsterdam, the Netherlands, said the downside is that hyperbaric oxygen therapy is offered only in large academic centers and is expensive. As the therapy is difficult to administer, it could also place a significant burden on clinicians.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.